Mitoxantrone
- Generic Name
- Mitoxantrone
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Loyola University
- Registration Number
- NCT00002474
- Locations
- 🇺🇸
Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Lymphoma Trials Office
- Target Recruit Count
- 500
- Registration Number
- NCT00006250
- Locations
- 🇬🇧
St. Thomas' Hospital, London, England, United Kingdom
🇬🇧Birmingham Heartlands Hospital, Birmingham, England, United Kingdom
🇬🇧Craigavon Area Hospital, Craigavon, Northern Ireland, United Kingdom
Combination Chemotherapy in Treating Older Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Registration Number
- NCT00010075
- Locations
- 🇫🇷
Hopital Tenon, Paris, France
🇫🇷Centre Hospitalier Victor Dupouy, Argenteuil, France
🇫🇷Hopital Saint Antoine, Paris, France
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00005802
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 213
- Registration Number
- NCT00005985
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 57
- Registration Number
- NCT00017563
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸Portland VA Medical Center, Portland, Oregon, United States
Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma
- Conditions
- Sarcoma, KaposiHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Lederle Laboratories
- Registration Number
- NCT00002259
- Locations
- 🇺🇸
Saint Luke's - Roosevelt Hosp Ctr, New York, New York, United States
Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas
- Conditions
- Lymphoma, Non-HodgkinHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Lederle Laboratories
- Registration Number
- NCT00002003
- Locations
- 🇺🇸
UMDNJ - New Jersy Med School, Newark, New Jersey, United States
🇺🇸New York Univ Med Ctr, New York, New York, United States
🇺🇸Saint Luke's - Roosevelt Hosp Ctr, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.